Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2019 - 2026)

Zentalis Pharmaceuticals' quarterly Capital Expenditures came in at $34000.0 in Q1 2026, down 81.22% quarter-over-quarter from $181000.0 in Q2 2024.

Zentalis Pharmaceuticals has reported Capital Expenditures for 7 years, with the latest figure at $34000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at $34000.0 (down 81.22% YoY), and the FY2024 full-year result was $221000.0, down 62.09% from the prior year.
  • Capital Expenditures for Q1 2026 stood at $34000.0, down from $181000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.3 million in Q3 2022, with the low at -$135000.0 in Q2 2022.
  • Average Capital Expenditures over 4 years is $338600.0, with a median of $166500.0 recorded in 2022.
  • Year-over-year, Capital Expenditures tumbled 101.49% in 2022 and surged 336.3% in 2023.
  • Tracing ZNTL's Capital Expenditures over 4 years: stood at $160000.0 in 2022, then gained by 8.12% to $173000.0 in 2023, then grew by 4.62% to $181000.0 in 2024, then slumped by 81.22% to $34000.0 in 2026.
  • The last three Capital Expenditures figures came in at $34000.0 (Q1 2026), $181000.0 (Q2 2024), and $40000.0 (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 21.83 Mn
10 Zentalis Pharmaceuticals 280.35 Mn 280.35 Mn - 34,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 34,000.00
Mar 31, 2026 34,000.00
Jun 30, 2024 181,000.00
Jun 30, 2024 181,000.00
Mar 31, 2024 40,000.00
Mar 31, 2024 40,000.00
Dec 31, 2023 173,000.00
Dec 31, 2023 173,000.00
Sep 30, 2023 91,000.00
Sep 30, 2023 91,000.00
Jun 30, 2023 319,000.00
Jun 30, 2023 319,000.00
Dec 31, 2022 160,000.00
Dec 31, 2022 160,000.00
Sep 30, 2022 2.30 Mn
Sep 30, 2022 2.30 Mn
Jun 30, 2022 -135,000.00
Jun 30, 2022 -135,000.00
Mar 31, 2022 226,000.00
Mar 31, 2022 226,000.00
Dec 31, 2021 2.19 Mn
Dec 31, 2021 2.19 Mn
Sep 30, 2021 3.92 Mn
Sep 30, 2021 3.92 Mn
Jun 30, 2021 -67,000.00
Jun 30, 2021 -67,000.00
Mar 31, 2021 67,000.00
Mar 31, 2021 67,000.00
Dec 31, 2020 661,000.00
Dec 31, 2020 661,000.00
Sep 30, 2020 41,000.00
Sep 30, 2020 41,000.00
Jun 30, 2020 25,000.00
Jun 30, 2020 25,000.00
Mar 31, 2020 31,000.00
Mar 31, 2020 31,000.00
Dec 31, 2019 -316,000.00
Dec 31, 2019 -316,000.00
Sep 30, 2019 107,000.00
Sep 30, 2019 107,000.00
Jun 30, 2019 202,000.00
Jun 30, 2019 202,000.00
Mar 31, 2019 7,000.00
Mar 31, 2019 7,000.00